Neuralstem, Inc. (CUR) Stock Price Down 2.7%
Neuralstem, Inc. (NASDAQ:CUR)’s share price was down 2.7% during mid-day trading on Monday . The company traded as low as $0.97 and last traded at $1.10. Approximately 122,500 shares changed hands during trading, a decline of 65% from the average daily volume of 353,065 shares. The stock had previously closed at $1.13.
Separately, ValuEngine downgraded Neuralstem from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CUR. Alethea Capital Management LLC lifted its position in shares of Neuralstem by 100.0% in the second quarter. Alethea Capital Management LLC now owns 328,788 shares of the company’s stock valued at $1,904,000 after acquiring an additional 164,394 shares in the last quarter. Blair William & Co. IL increased its holdings in shares of Neuralstem by 171.0% in the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock valued at $506,000 after purchasing an additional 55,115 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Neuralstem by 1.1% in the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock valued at $2,000,000 after purchasing an additional 3,853 shares during the last quarter. Finally, National Asset Management Inc. increased its holdings in shares of Neuralstem by 9.2% in the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock valued at $134,000 after purchasing an additional 1,937 shares during the last quarter. Institutional investors and hedge funds own 7.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Neuralstem, Inc. (CUR) Stock Price Down 2.7%” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/neuralstem-inc-cur-stock-price-down-2-7.html.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.